Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer

Exclusion Criteria

• •Patients previously treated for NSCLC
• •Patient with oncogene addiction or a first-line targetable rearrangement
• •Patient not suitable for immunotherapy alone
• •Patient having received corticosteroid treatment in the 15 days prior to FeNO.
• •Patient on inhaled corticosteroid at time of inclusion.
• •Blood eosinophilia \> 500 /mm3
• •Patient on 24-hour oxygen therapy
• •Contraindication to immunotherapy
• •Inability to perform FeNO measurement manoeuvres
• •Pregnant, parturient or breast-feeding women
• •Person under judicial protection (curatorship, guardianship)
• •Person subject to limited judicial protection
• •Adult unable to express their non-opposition
• •Patient refusing to participate in the study